<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F8302422-55CA-4DFF-817B-9EBECA831882"><gtr:id>F8302422-55CA-4DFF-817B-9EBECA831882</gtr:id><gtr:name>The Global Alliance for TB Drug Development</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46B41008-0EB4-4E28-BBFB-E98366999EC5"><gtr:id>46B41008-0EB4-4E28-BBFB-E98366999EC5</gtr:id><gtr:name>Durham University</gtr:name><gtr:address><gtr:line1>Old Shire Hall</gtr:line1><gtr:line2>Old Elvet</gtr:line2><gtr:line4>Durham</gtr:line4><gtr:line5>County Durham</gtr:line5><gtr:postCode>DH1 3HP</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D82F94EC-9E43-4133-AAC5-FB34D0074719"><gtr:id>D82F94EC-9E43-4133-AAC5-FB34D0074719</gtr:id><gtr:name>Government of the UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850"><gtr:id>5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850</gtr:id><gtr:name>University of Strathclyde</gtr:name><gtr:address><gtr:line1>16 Richmond Street</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G1 1XQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EAF17943-4FDF-4E08-A8D2-281D7130987C"><gtr:id>EAF17943-4FDF-4E08-A8D2-281D7130987C</gtr:id><gtr:name>Birkbeck, University of London</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/492BC9FE-0BC5-4690-B919-C5E2AB232070"><gtr:id>492BC9FE-0BC5-4690-B919-C5E2AB232070</gtr:id><gtr:name>Council of Scientific and Industrial Research (CSIR)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:department>Sch of Medicine</gtr:department><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060"><gtr:id>C0E4FAD2-3C8B-410A-B6DF-3B9B9E433060</gtr:id><gtr:name>University of St Andrews</gtr:name><gtr:address><gtr:line1>College Gate</gtr:line1><gtr:line4>St. Andrews</gtr:line4><gtr:line5>Fife</gtr:line5><gtr:postCode>KY16 9AJ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F8302422-55CA-4DFF-817B-9EBECA831882"><gtr:id>F8302422-55CA-4DFF-817B-9EBECA831882</gtr:id><gtr:name>The Global Alliance for TB Drug Development</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46B41008-0EB4-4E28-BBFB-E98366999EC5"><gtr:id>46B41008-0EB4-4E28-BBFB-E98366999EC5</gtr:id><gtr:name>Durham University</gtr:name><gtr:address><gtr:line1>Old Shire Hall</gtr:line1><gtr:line2>Old Elvet</gtr:line2><gtr:line4>Durham</gtr:line4><gtr:line5>County Durham</gtr:line5><gtr:postCode>DH1 3HP</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D82F94EC-9E43-4133-AAC5-FB34D0074719"><gtr:id>D82F94EC-9E43-4133-AAC5-FB34D0074719</gtr:id><gtr:name>Government of the UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850"><gtr:id>5BB4F8BF-B4E0-4EAF-9AF5-885E19D64850</gtr:id><gtr:name>University of Strathclyde</gtr:name><gtr:address><gtr:line1>16 Richmond Street</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G1 1XQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EAF17943-4FDF-4E08-A8D2-281D7130987C"><gtr:id>EAF17943-4FDF-4E08-A8D2-281D7130987C</gtr:id><gtr:name>Birkbeck, University of London</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/492BC9FE-0BC5-4690-B919-C5E2AB232070"><gtr:id>492BC9FE-0BC5-4690-B919-C5E2AB232070</gtr:id><gtr:name>Council of Scientific and Industrial Research (CSIR)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6CD959F1-84FE-486D-A904-62FA72C33862"><gtr:id>6CD959F1-84FE-486D-A904-62FA72C33862</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>Henry</gtr:otherNames><gtr:surname>Gillespie</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/71DB9C23-47FA-42B0-A68F-D042A9DBF971"><gtr:id>71DB9C23-47FA-42B0-A68F-D042A9DBF971</gtr:id><gtr:firstName>Karl Joseph</gtr:firstName><gtr:surname>Hale</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6D847E0F-0B3B-41B7-A23D-548BC4B1B4A5"><gtr:id>6D847E0F-0B3B-41B7-A23D-548BC4B1B4A5</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:surname>Butcher</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/57E997FA-7341-4710-AEA2-5F84D8309962"><gtr:id>57E997FA-7341-4710-AEA2-5F84D8309962</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Taylor</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7F688C64-0271-459E-9626-85470DAAC64B"><gtr:id>7F688C64-0271-459E-9626-85470DAAC64B</gtr:id><gtr:firstName>Sanjib</gtr:firstName><gtr:surname>Bhakta</gtr:surname><gtr:orcidId>0000-0002-1165-9295</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9729A4DB-2FB1-40BC-8B89-E8FA153AD4C2"><gtr:id>9729A4DB-2FB1-40BC-8B89-E8FA153AD4C2</gtr:id><gtr:firstName>Gurdyal Singh</gtr:firstName><gtr:surname>Besra</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2803AD1C-816F-47BC-A701-8C4700E95F14"><gtr:id>2803AD1C-816F-47BC-A701-8C4700E95F14</gtr:id><gtr:firstName>Edith</gtr:firstName><gtr:surname>Sim</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CD6D77C9-AC58-44F7-B35D-A1B42FFC8FA3"><gtr:id>CD6D77C9-AC58-44F7-B35D-A1B42FFC8FA3</gtr:id><gtr:firstName>Geoffrey</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>Coxon</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/104F1B07-61E4-4C19-B9B8-E91AECC16A13"><gtr:id>104F1B07-61E4-4C19-B9B8-E91AECC16A13</gtr:id><gtr:firstName>Timothy</gtr:firstName><gtr:otherNames>Daniel</gtr:otherNames><gtr:surname>McHugh</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DBEFCA09-243D-4DEF-A087-97C648D47453"><gtr:id>DBEFCA09-243D-4DEF-A087-97C648D47453</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:otherNames>Robert</gtr:otherNames><gtr:surname>Coates</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0802079"><gtr:id>2F97245D-A032-4EC7-A34F-FFC2CC875B71</gtr:id><gtr:title>Tuberculosis Drug discovery-UK (TBD-UK)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0802079</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>N/A</gtr:technicalSummary><gtr:fund><gtr:end>2012-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-07-20</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>204740</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs><gtr:artisticAndCreativeProductOutput><gtr:description>a short film was produced and launched at the World TB Summit in London to commemorate the World TB Day in 2014</gtr:description><gtr:id>2EC3B6A4-3D29-418F-A06A-994118F7E3AF</gtr:id><gtr:impact>enhanced public engagement and understanding in TB control, education and laboratory research.</gtr:impact><gtr:outcomeId>5460b3b633bf84.92955975</gtr:outcomeId><gtr:title>A short film launched to commemorate World TB Day</gtr:title><gtr:type>Film/Video/Animation</gtr:type><gtr:url>http://www.youtube.com/watch?v=gvvvTM__GFI</gtr:url><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput></gtr:artisticAndCreativeProductOutputs><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>Inhibitors of Cell wall PG (Med Chem)</gtr:description><gtr:id>90219AF7-86BB-4ABD-877B-C846E91C4211</gtr:id><gtr:impact>An interdisciplinary collaboration in between medicinal chemistry, molecular microbiology and chemical biology. Resulted in successful joint supervision of one PhD student, two post-graduate project students, three original research articles and a joint patent application.</gtr:impact><gtr:outcomeId>UAiZjeH81sn-1</gtr:outcomeId><gtr:partnerContribution>Synthesized novel derivatives (more than 100) of aporphine alkaloids as antituberculars.</gtr:partnerContribution><gtr:piContribution>evaluation of the biological properties of the novel compounds against the whole mycobacterial cell as well as against the target enzymes (ATP dependent mur ligases). Currently supervising an interdisciplinary PhD student. A joint UK patent application and an original research article are under review.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Pharmacy</gtr:department><gtr:description>Natural Product Chemistry UCL-SOP</gtr:description><gtr:id>C82DC05C-74B6-43CC-A592-5D565CC0AD7F</gtr:id><gtr:impact>An interdisciplinary collaboration in between natural product chemistry, medicinal chemistry and molecular microbiology:

Original research articles:
1. Guzman, J.D.; Mortazavi, P.N.; Munshi, T.; Evangelopoulos, D.; McHugh, T.D.; Gibbons, S.; Malkinson, J. and Bhakta, S. (2014) 2-Hydroxy-substituted cinnamic acids and acetanilides are selective growth inhibitors of Mycobacterium tuberculosis. ChemMedComm 5 (1) 47 - 50.

2. Shiu WK, Malkinson JP, Rahman MM, Curry J, Stapleton P, Gunaratnam M, Neidle S, Mushtaq S, Warner M, Livermore DM, Evangelopoulos D, Basavannacharya C, Bhakta, S., Schindler BD, Seo SM, Coleman D, Kaatz GW, Gibbons S. (2013) A new plant-derived antibacterial is an inhibitor of efflux pumps in Staphylococcus aureus. Int J Antimicrob Agents. 42(6):513-8. 

3. Guzman JD, Evangelopoulos D, Gupta A, Birchall K, Mwaigwisya S, Saxty B, McHugh TD, Gibbons S, Malkinson J, Bhakta S.* (2013) Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open, 3(6). 

4. Guzman JD, Evangelopoulos D, Gupta A, Prieto JM, Gibbons S. and Bhakta S. (2013) Antimycobacterials from Lovage Root (Ligusticum officinale Koch). Phytotherapy Research, 27(7):993-8.

5. Wube, A.; Guzman, J.D.; H&amp;uuml;fner, A.; Hochfellner, C.; Blunder, M.; Bauer, R.; Gibbons, S.; Bhakta, S. and Bucar, F. (2012) Synthesis and biological evaluation of a new series of N-alkyl-2-alkynyl-4-(1H)-quinolones. Molecules 17(7):8217-40.1. 

6. Osman, K., Evangelopoulos, D., Basavannacharya, C., Gupta, A., McHugh, T.D., Bhakta, S. and Gibbons, S. (2012) An antibacterial from Hypericum acmosepalum inhibits ATP dependent MurE ligase from Mycobacterium tuberculosis. Int. J. Antimicrob. Agents. 39(2):124-9.

7. Guzman, J.D., Wube, A., Evangelopoulos, D., Gupta, A., H&amp;uuml;fner, A., Basavannacharya, C., Rahman, M.M., Thomaschitz, C., Bauer, R., McHugh, T.D., Nobeli, I., Prieto, J.M., Gibbons, S., Bucar, F.&amp;para; and Bhakta, S.&amp;para;* (2011) Interaction of N-methyl-2-alkenyl-4-quinolones with ATP-dependent MurE ligase of Mycobacterium tuberculosis: antibacterial activity, molecular docking and inhibition kinetics. J. Antimicrob. Chemotherapy 66(8):1766-72. (&amp;para; equal contribution).

8. Guzman, J.D.; Gupta, A.; Evangelopoulos, D.; Basavannacharya, C.; Pabon, L.C.; Plazas, E.A.; Mu&amp;ntilde;oz, D.R.; Delgado, W.A.; Cuca, L.E.; Ribon, W.; Gibbons, S. and Bhakta, S.* (2010) Anti-tubercular screening of natural products from Colombian plants: 3-5 methoxy nordomesticine, an inhibitor of MurE ligase of Mycobacterium tuberculosis. J. Antimicrob. Chemotherapy 65(10), 2101-7.

9. O'Donnell, G., Poeschl, R., Zimhony, O., Gunaratnam, M., Moreira, J.B., Neidle, S., Evangelopoulos, D., Bhakta, S., Malkinson, J.P., Boshoff, H.I., Lenaerts, A. &amp;amp; Gibbons, S. (2009). Bioactive pyridine-N-oxide disulfides from Allium stipitatum. J Nat Prod. 72(3), 360-5. 

Review Article:

1. Guzman, J.D.; Gupta, A.; Bucar, F.; Gibbons, S. and Bhakta, S. (2012) Anti-mycobacterials from natural sources: ancient times, antibiotic era and novel scaffolds. Frontiers in Bioscience 17, 1861-1881.</gtr:impact><gtr:outcomeId>KzymBipZKDL-1</gtr:outcomeId><gtr:partnerContribution>training and advice on extraction, purification and charaterisation of natural products. Contributing to a library of natural products inhibitors for a comprehensive biological evaluation.</gtr:partnerContribution><gtr:piContribution>evaluation of the biological properties of the crude extracts, partially purified fractions, pure natural product compounds against the whole mycobacterial cell as well as against the target enzymes (ATP dependent mur ligases). Jointly supervised two interdisciplinary Bloomsbury PhD students and currently supervising two international (Govt funded) PhD students. Generated 9 joint original research publications, 1 review article and a few others under preparation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of St Andrews</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>TBD-UK, Tuberculosis drug discovery consortium</gtr:department><gtr:description>TB Drug Discovery UK (TBD-UK)</gtr:description><gtr:id>58F20BBC-51B3-4E30-8FA8-928C13129BE6</gtr:id><gtr:impact>As above</gtr:impact><gtr:outcomeId>cuRekZNL8rc-1</gtr:outcomeId><gtr:partnerContribution>Coordinating research, identifying new research partners, addressing key research questions, developing collaborations and making policy change in the research area.</gtr:partnerContribution><gtr:piContribution>As above</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Birkbeck, University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Biological Sciences</gtr:department><gtr:description>Structural Biology, Birkbeck</gtr:description><gtr:id>596E7C8E-64B6-429A-B7A0-7E9BDE43777D</gtr:id><gtr:impact>An interdisciplinary collaboration in between Structural Biology and Molecular Microbiology:

Original Research Articles:
1. Basavannacharya, C., Robertson, G., Munshi, T., Keep, N.H. &amp;amp; Bhakta, S. (2010). ATP-dependent MurE ligase in Mycobacterium tuberculosis: biochemical and structural characterisation. Tuberculosis (Edinb) 90(1), 16-24. 

2. Basavannacharya, C., Moody, P. R., Munshi, T., Cronin, N., Keep, N. H. &amp;amp; Bhakta, S. (2010). Roles of amino acid residues essential for the enzyme activity of MurE of Mycobacterium tuberculosis identified. Protein &amp;amp; Cell 1(10)(accepted in press; featured as cover page article) 

3. Evangelopoulos D, Cronin N, Daviter T, Sim E, Keep NH and Bhakta S. (2011) Characterization of an oxidoreductase from the arylamine N-acetyltransferase operon in Mycobacterium smegmatis. FEBS J. 278(24):4824-32. 

4. Munshi, T.; Gupta, A.; Guzman, J. D.; Evangelopoulos, D.; Gibbons, S.; Keep, N.H. and Bhakta, S.* (2013) Characterisation of ATP-Dependent Mur Ligases Involved in the Biogenesis of Cell Wall Peptidoglycan in Mycobacterium tuberculosis.
PloS ONE 8(3): e60143. doi:10.1371/journal.pone.0060143</gtr:impact><gtr:outcomeId>NamoyEK77rt-1</gtr:outcomeId><gtr:partnerContribution>Training and advice on setting crystallisation trials and solving X-Ray diffraction data for 3D structural elucidation of mycobacterial proteins</gtr:partnerContribution><gtr:piContribution>significant intellectual input into our common research interest in cell wall peptidoglycan biosynthesis, degradation and recycling in Mycobacterium tuberculosis; Supervised three PhD Students (awarded PhDs in between 2010 and 2013) worked on structural and functional characterisation of mycobacterial proteins. Generated four original research articles and a few others are in preparation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Council of Scientific and Industrial Research (CSIR)</gtr:collaboratingOrganisation><gtr:country>South Africa, Republic of</gtr:country><gtr:description>Workshop CSIR Nanomedicine Platform for Infectious Diseases of Poverty</gtr:description><gtr:id>4F975253-5B77-419F-AC73-548F3FCE706A</gtr:id><gtr:impact>Workshop to be held March 2011. Knowledge exchange</gtr:impact><gtr:outcomeId>Nzpi5tMj1h5-1</gtr:outcomeId><gtr:piContribution>Engaged as research group leader to deliver CSIR workshop under umbrella of knowledge exchange</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Durham University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>New antituberculars with novel MoA_Durham</gtr:description><gtr:id>EFC2DBA2-32B3-45B0-BFE8-A9559C1CD5AB</gtr:id><gtr:impact>An interdisciplinary academic research collaboration (Natural Product Chemistry, Computational Biology &amp;amp; Molecular Microbiology) generated original research articles and a successful small research grant. One review article is currently in preparation 

Original Research Articles:
1. Kottakota SK, Benton M, Evangelopoulos D, Guzman JD, Bhakta S, McHugh TD, Gray M, Groundwater PW, Marrs EC, Perry JD and Harburn JJ. (2012) Versatile routes to marine sponge metabolites through benzylidene rhodanines. Org Lett.;14(24):6310-3. 

2. Kottakota, S.K.; Evangelopoulos, D.; Alnimr, A.; Bhakta, S.; McHugh, T.D.; Gray, M.; Groundwater, P.W.; Marrs, E.C.L.; Perry, J.D.; Spilling, C.D. and Harburn, J.J. (2012) Synthesis and biological evaluation of Purpurealidin E-derived marine sponge metabolites: Aplysamine-2, Aplyzanzine A, Suberedamines A,B and Anomoian A. J. Nat Prod. 75(6):1090-101.</gtr:impact><gtr:outcomeId>5460925f448cc0.53937790-1</gtr:outcomeId><gtr:partnerContribution>Extract, fractionate, purify, semi-synthesize as well as design natural product inhibitors against target enzymes as well as against whole cell phenotype for validation.</gtr:partnerContribution><gtr:piContribution>Comprehensive evaluation of the biological properties of pure natural product compounds against the whole mycobacterial cell, drug efflux mechanisms and biofilm formation as well as against the target enzymes (ATP dependent mur ligases, N-acetyl transferase, Oxido-reductases). Generated three joint research publications. One review article and a few other research articles are in preparation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Government of the UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK Coalition to Stop TB</gtr:description><gtr:id>7ABF10A6-7F87-48E7-A4F4-D8F21C910D2B</gtr:id><gtr:impact>As above</gtr:impact><gtr:outcomeId>oxjJtU6vf9h-1</gtr:outcomeId><gtr:piContribution>New collaboration previously not undertaken by TB researchers in the past. TBD-UK Chair and Deputy Chair sit on steering group and will be advising APPG TB and other government advisory bodies and government departments on roles, needs and contributions to be made from UK TB researchers in drug discovery.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Global Alliance for TB Drug Development</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>TB Alliance (Global Alliance for TB Drug Development)</gtr:description><gtr:id>854E703B-8731-4032-A1A0-3BABCDB457A5</gtr:id><gtr:impact>As above</gtr:impact><gtr:outcomeId>TZNmYhYmJdt-1</gtr:outcomeId><gtr:partnerContribution>The Alliance facilitated key in-vitro assessment of ATC compounds to address specific MRC DPFS panel requests. 
They have assisted Deputy Chair TBD-UK in the construction of the TBD-UK Blueprint which now serves as a guide for the development of all UK research. 
They are working with Deputy Chair on the creation of a target product profile for the ATCs and other TB drugs.</gtr:partnerContribution><gtr:piContribution>As above</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Strathclyde</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Traditional herbs and new antibiotic_Strathclyde</gtr:description><gtr:id>80186F01-B2E5-411E-85C6-84CBD386838B</gtr:id><gtr:impact>This is an interdisciplinary collaboration between traditional herbal natural products and microbiology.
Generated one original research article and a joint grant application (in preparation).
Original Research Article:
1. Zhao J, Evangelopoulos D, Bhakta S, Gray AI and Seidel V. (2014) Antitubercular activity of Arctium lappa and Tussilago farfara extracts and constituents. J Ethnopharmacol.;155(1):796-800.</gtr:impact><gtr:outcomeId>54609ca78da586.00550286-1</gtr:outcomeId><gtr:partnerContribution>provide natural product inhibitors (crude extracts , partially purified fractions and pure compounds) for bioassay guided evaluation against mycobacteria.</gtr:partnerContribution><gtr:piContribution>Bioassay guided evaluation of natural products (crude extracts, partially purified fractions and purified molecules).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Pharmacy</gtr:department><gtr:description>Substrates and analogues of cellwall-PG enzymes</gtr:description><gtr:id>6C2E9CEA-BDBF-4239-903E-F7E78386F901</gtr:id><gtr:impact>An interdisciplinary collaboration in between synthetic chemistry and molecular microbiology. A PhD student is currently under joint supervision and generated one review article and one research article currently in preparation.</gtr:impact><gtr:outcomeId>nBcse3XCEBe-1</gtr:outcomeId><gtr:partnerContribution>Synthesizing substrates and substrate analogues (using solid phase peptide synthesis)</gtr:partnerContribution><gtr:piContribution>assaying the activity and inhibition of substrates and substrate analogues against ATP-dependent Mur ligases and Murein peptide ligases from bacteria.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>TBD-UK Website Development</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C3D1E109-CCEE-4434-9969-FCD39882E461</gtr:id><gtr:impact>Development of the TBD-UK website to raise awareness of the research that UK TB researchers in drug discovery and developmen undertaken. Secure area also developed to enable researchers to share key articles and work.

Development of strong links with other TB focused organisations (such as Stop TB, UK Coalition to Stop TB, TB Alert and the APPG. 
Continued increase in website visits with approx 300-400 hits per month and a 65% new hit rate.</gtr:impact><gtr:outcomeId>qwWu5U9Yz4i</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Article in Microbiology Today</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BA1F7D63-249F-4335-92DA-CCDE35A5AF7D</gtr:id><gtr:impact>Article &amp;quot;Tuberculosis: forgotten not gone&amp;quot; in Microbiology Today the House Journal of SOciety of General Microbiology which is made available to microbiologists internationally but, importantly given to schools

No notable impacts</gtr:impact><gtr:outcomeId>ZcjtwMc2dQp</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Evidence to the All Party Parliamentary Committee for tuberculosis</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4AA0B379-1A34-4F28-8604-47737DCEF21F</gtr:id><gtr:impact>Advice was given of the importance of support for further research tuberculosis drug development

Further invitations to APPGTB have been made</gtr:impact><gtr:outcomeId>hscUXkbHchv</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Higher Education Workshop (Ealing)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7CEBFE26-DFCB-4E4E-AF1A-E77CFFCC13CB</gtr:id><gtr:impact>Organisation of a Higher Education workshop focusing on &amp;quot;Extensively drug resistant Tuberculosis (XDR-TB): cure for today or tomorrow)&amp;quot;. This included the publising of an article in the London Sharad Utsav 2009 brochure (5000 copies printed)

Increased awareness of the issue of TB and the work of TBD-UK</gtr:impact><gtr:outcomeId>qrbB2b9DbX6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PreDiCT-TB</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>BD0C1FDD-4835-4E45-A6B8-E1B47042AF76</gtr:id><gtr:outcomeId>q65E9YK2pD60</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>505280</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>E09FD621-7A30-410D-B31D-2C18762D2044</gtr:id><gtr:outcomeId>SeY5cNtGhGC0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>495902</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>6F3C2359-F62A-4F3C-8456-11D449D6E9E7</gtr:id><gtr:outcomeId>T6PH92NYNXK0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5902837</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EU Innovative Medicines Initiative</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>05C37997-CF06-49F0-9AFA-EFA9B9FC84C3</gtr:id><gtr:outcomeId>C8URvDu1YBN0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>87000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Scottish Universities Life Science Alliance (SULSA)/Biotechnology and Biological Sciences Research Council (BBSRC) (Bioscape with SULSA and Helpbery Therapeutics PLC)</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>9618075A-E007-43CC-A198-E3054566DD73</gtr:id><gtr:outcomeId>TiFs76BGDxe0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC New Investigators Research Grant</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>405BB6C1-5CC6-4D8D-9BD6-7F4993417778</gtr:id><gtr:outcomeId>RA5LGuewqME0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A solid culture based whole cell screening assay (HT-SPOTi; 24, 48 &amp;amp; 96 well format) to test libraries of inhibitors against the slow growing mycobacteria including Mycobacterium aurum and Mycobacterium tuberculosis.</gtr:description><gtr:grantRef>G0802079</gtr:grantRef><gtr:id>0BC39B81-6364-41B6-BF73-35443B69131D</gtr:id><gtr:impact>Availability of this whole cell screening assay is highly beneficial for TB inihibitor screening purposes. A large number of academic &amp;amp; industrial research collaborations to be established on the basis of this facility.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>noVPxqN1Dx1</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>Whole cell screening of inhibitors against the growth of mycobacteria (HT-SPOTi)</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Input to the APPG on Global Tuberculosis call for evidence</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>D281646B-4A9D-4492-8B0E-9D0FC4B82849</gtr:id><gtr:outcomeId>PsEXakvawVi</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Mentoring Session at INTERNATIONAL UNION on Antibitic Resistance in TB</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>2CEF096F-6281-4DFD-820D-9C04D3E9FAA5</gtr:id><gtr:outcomeId>FXnaKvq6dyc</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.stoptb.org/assets/documents/</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Engaging local MP and a Member of House of Lords in TB control</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E704413D-A162-4B6F-BEFB-A3E4ED669A06</gtr:id><gtr:outcomeId>BgvCnQcMudS</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>This is a natural product based formulation that activates macrophages under bacterial infection and thus enables the reduction of infection.</gtr:description><gtr:id>36FDC0A3-0CBE-4ABD-85EA-A335AA3B0568</gtr:id><gtr:impact>This enables a new methodology and approach to be investigated.</gtr:impact><gtr:outcomeId>WD7sf1gZi2m</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Natural product formulation - Pelargonium-derived stimulators of macrophage function</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The ATCs are a new class of anti-tubercular and the first new drug output of TBD-UK collaboration grant. In vitro activity (intra and extra cellular) have been evaluated, toxicity and selectivity evaluated and routes of metabolism identified in vitro. This work was initially funded in part from the Wellcome trust. Other available sources of funding have been utilised on a &amp;quot;good will and collaborative&amp;quot; nature.</gtr:description><gtr:id>43E9F2AB-D588-4874-9BF4-DF9E6A0C2A2B</gtr:id><gtr:impact>This has proved that the collaboration grant network can lead to real outcomes. The development of this program and recent invitation to full stage application for an MRC DPFS grant has also facilitated the construction of the TB drug discovery and development blue print which is now beign used to guide and coordinate all UK TB reserach in the UK. The development of the DPFS application has also resulted in strong links with the Global TB Alliance for Drug Development and the formation of specific TB drug target product profile (TPP). This may be used to support other outcomes from the collaboration grant. Importantly, this critical activity was not engaged collaboration grant pre-funding</gtr:impact><gtr:outcomeId>rYSzNt2JrcE</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Identification and development of new ATC class of antitubercular agents</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Mouse, guinea pig and primate models developed for new compound evaluation,</gtr:description><gtr:id>39EAD6FB-D43E-4BB7-B465-1A808F4644F9</gtr:id><gtr:impact>Critical assessment models (previously unavailable) ready for use by TB drug discovery researchers.</gtr:impact><gtr:outcomeId>acsqTm1pDV9</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>In-vivo models of drug evaluation</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Assay for screening of compounds.</gtr:description><gtr:id>68A1264A-9D0C-4877-A90C-C2F975BC2D6C</gtr:id><gtr:impact>Novel inhibitors identified</gtr:impact><gtr:outcomeId>U7wZTT6Zm81</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Mur ligase assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Critical target for M. tuberculosis drug discovery identified</gtr:description><gtr:id>41A22232-78C4-4994-B82B-83E3ABC1634B</gtr:id><gtr:impact>This enables a new approach to discover new TB drugs</gtr:impact><gtr:outcomeId>H9tH4BjCFvz</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>GlgE target</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>X-ray crystal structures of Mur ligases deposited in protein crystal databank with codes 2XW7, 2WTZ, 2XJA</gtr:description><gtr:id>A5545B1D-D09C-4197-AFE0-2CB6BA758B5D</gtr:id><gtr:impact>Has enabled structure based design of inhibitors</gtr:impact><gtr:outcomeId>nxnTqSSenjT</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>X-ray crystal structures</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=2XW7</gtr:url><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>886ABA22-A346-4188-9F2F-12082D8E4263</gtr:id><gtr:title>Novel Anti-Tuberculosis Nanodelivery Formulation of Ethambutol with Graphene Oxide.</gtr:title><gtr:parentPublicationTitle>Molecules (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e280aeb25723ca3e299a4ce7d6024ac"><gtr:id>2e280aeb25723ca3e299a4ce7d6024ac</gtr:id><gtr:otherNames>Saifullah B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1420-3049</gtr:issn><gtr:outcomeId>5aa589c0973114.63024881</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2835AD6-FE43-43F2-9BF9-7CCB4D93A8A2</gtr:id><gtr:title>A new plant-derived antibacterial is an inhibitor of efflux pumps in Staphylococcus aureus.</gtr:title><gtr:parentPublicationTitle>International journal of antimicrobial agents</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6605ef80bc51a561996494b95215543"><gtr:id>f6605ef80bc51a561996494b95215543</gtr:id><gtr:otherNames>Shiu WK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0924-8579</gtr:issn><gtr:outcomeId>pm_14203_23_24119569</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7B1E2D0-DA1A-4159-BAAD-E4E3E64AC732</gtr:id><gtr:title>TB Summit 2014: prevention, diagnosis, and treatment of tuberculosis-a meeting report of a Euroscicon conference.</gtr:title><gtr:parentPublicationTitle>Virulence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ef4886af58d356598faedafe2cb830d"><gtr:id>3ef4886af58d356598faedafe2cb830d</gtr:id><gtr:otherNames>Maitra A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2150-5594</gtr:issn><gtr:outcomeId>5460790139b4d0.31540898</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C142C9F1-22B2-4CBB-8182-41C46E7C4886</gtr:id><gtr:title>Total synthesis of (+)-A83586C, (+)-kettapeptin and (+)-azinothricin: powerful new inhibitors of beta-catenin/TCF4- and E2F-mediated gene transcription.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a413e438aa59c92c7521a2f8ba3a93d6"><gtr:id>a413e438aa59c92c7521a2f8ba3a93d6</gtr:id><gtr:otherNames>Hale KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>jfcFVQ6oo1W</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C1D1537-80B2-48D9-9339-4EDFCEE754D5</gtr:id><gtr:title>ProTides of N-(3-(5-(2'-deoxyuridine))prop-2-ynyl)octanamide as potential anti-tubercular and anti-viral agents.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21ea743c0b8ec2c794e384c67efc5506"><gtr:id>21ea743c0b8ec2c794e384c67efc5506</gtr:id><gtr:otherNames>McGuigan C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>5460790189c855.60993318</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4F48B20-7820-4181-AABA-074405593248</gtr:id><gtr:title>HIV-associated tuberculous meningitis--diagnostic and therapeutic challenges.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26d29de4809bfdda46518e1a7a781512"><gtr:id>26d29de4809bfdda46518e1a7a781512</gtr:id><gtr:otherNames>Marais S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>KHjtSmUi1cm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2458F8B-E1A5-44BA-80F2-86E0B3612072</gtr:id><gtr:title>Characterization of an oxidoreductase from the arylamine N-acetyltransferase operon in Mycobacterium smegmatis.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99e1ce46a078a2c54aa3362453f9805c"><gtr:id>99e1ce46a078a2c54aa3362453f9805c</gtr:id><gtr:otherNames>Evangelopoulos D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>pm_14203_23_21972977</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A86D459-47BA-4FDA-B736-0E60CFA3672C</gtr:id><gtr:title>Investigation of the mycobacterial enzyme HsaD as a potential novel target for anti-tubercular agents using a fragment-based drug design approach.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4c8fe4afdf2453052459abf73077f66c"><gtr:id>4c8fe4afdf2453052459abf73077f66c</gtr:id><gtr:otherNames>Ryan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>5aa589c1047d05.81524576</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C798EA21-A3CA-4F81-A67E-41CD39F9291F</gtr:id><gtr:title>Host Antimicrobial Peptides: The Promise of New Treatment Strategies against Tuberculosis.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/022cc392a4dc6fc03fd4790460cb8546"><gtr:id>022cc392a4dc6fc03fd4790460cb8546</gtr:id><gtr:otherNames>Arranz-Trull?n J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5aa589c065f7f1.58324102</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21A407A9-84CA-41EA-BBF8-5D09011A90E4</gtr:id><gtr:title>Strategies and challenges involved in the discovery of new chemical entities during early-stage tuberculosis drug discovery.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87629f27a2c658094b401add6b845f4f"><gtr:id>87629f27a2c658094b401add6b845f4f</gtr:id><gtr:otherNames>Coxon GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_12466_26_22448016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23B1310D-BCBE-4908-9281-BC630802E455</gtr:id><gtr:title>2-Hydroxy-substituted cinnamic acids and acetanilides are selective growth inhibitors of Mycobacterium tuberculosis</gtr:title><gtr:parentPublicationTitle>Med. Chem. Commun.</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42d0b336b5ea4cff2cd164dbf50afcb9"><gtr:id>42d0b336b5ea4cff2cd164dbf50afcb9</gtr:id><gtr:otherNames>Guzman J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>doi_14203_c3md00251a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD49C191-5627-4ADD-B700-933F074F68B8</gtr:id><gtr:title>Synthesis and biological evaluation of purpurealidin E-derived marine sponge metabolites: aplysamine-2, aplyzanzine A, and suberedamines A and B.</gtr:title><gtr:parentPublicationTitle>Journal of natural products</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77dfe3df46d3fe140733e15f40cc675f"><gtr:id>77dfe3df46d3fe140733e15f40cc675f</gtr:id><gtr:otherNames>Kottakota SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0163-3864</gtr:issn><gtr:outcomeId>pm_14203_23_22620987</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C49D9F2E-95F8-468A-A7DC-20762837EC69</gtr:id><gtr:title>Application of continuous culture for measuring the effect of environmental stress on mutation frequency in Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f98ba01f8faae0419e04bb9abbaf228"><gtr:id>4f98ba01f8faae0419e04bb9abbaf228</gtr:id><gtr:otherNames>Bacon J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>ZAdmeit8EFW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C26527B5-404D-4D76-A486-C9B729535E69</gtr:id><gtr:title>Inhibition of Escherichia coli glycosyltransferase MurG and Mycobacterium tuberculosis Gal transferase by uridine-linked transition state mimics.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/676407c0259a1bdcb89937ad70f93e17"><gtr:id>676407c0259a1bdcb89937ad70f93e17</gtr:id><gtr:otherNames>Trunkfield AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>D2365LSutGA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE3E0253-B0B8-482F-A610-302662A0E4EF</gtr:id><gtr:title>Tuberculosis in Dr Granville's mummy: a molecular re-examination of the earliest known Egyptian mummy to be scientifically examined and given a medical diagnosis.</gtr:title><gtr:parentPublicationTitle>Proceedings. Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2856cedaf38ea9c58c0e15599a928e0e"><gtr:id>2856cedaf38ea9c58c0e15599a928e0e</gtr:id><gtr:otherNames>Donoghue HD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0962-8452</gtr:issn><gtr:outcomeId>Y7J6Ff9Zmxv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CCF17ABC-BA42-43B6-B60F-50E9D790C340</gtr:id><gtr:title>Synthesis and antibacterial evaluation of a new series of N-Alkyl-2-alkynyl/(E)-alkenyl-4-(1H)-quinolones.</gtr:title><gtr:parentPublicationTitle>Molecules (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d9a71ba9d720cd42af2a61cf71184db"><gtr:id>2d9a71ba9d720cd42af2a61cf71184db</gtr:id><gtr:otherNames>Wube A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1420-3049</gtr:issn><gtr:outcomeId>pm_14203_23_22777190</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>438618CC-4BD0-45E7-9237-76E257D1827A</gtr:id><gtr:title>Genome-Wide Identification by Transposon Insertion Sequencing ofK1 Genes Essential forGrowth, Gastrointestinal Colonizing Capacity and Survival in Serum.</gtr:title><gtr:parentPublicationTitle>Journal of bacteriology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f53791d42671a2ce6eb2a3c8fc00cd18"><gtr:id>f53791d42671a2ce6eb2a3c8fc00cd18</gtr:id><gtr:otherNames>McCarthy AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0021-9193</gtr:issn><gtr:outcomeId>5a79ac473a6cc5.32106735</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B0EC64D-85F2-405F-BC3A-8DE1B5A8FF3A</gtr:id><gtr:title>Contrasting transcriptional responses of a virulent and an attenuated strain of Mycobacterium tuberculosis infecting macrophages.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b8fa5a26f1efa25e596a80cccb51e50"><gtr:id>8b8fa5a26f1efa25e596a80cccb51e50</gtr:id><gtr:otherNames>Li AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>Drw7Kg8CWai</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B95AD850-4296-47EA-89BA-ABFB635D8CAC</gtr:id><gtr:title>Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!</gtr:title><gtr:parentPublicationTitle>International journal of antimicrobial agents</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/425b8165b063b944df38c6d871dee6bc"><gtr:id>425b8165b063b944df38c6d871dee6bc</gtr:id><gtr:otherNames>Amaral L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0924-8579</gtr:issn><gtr:outcomeId>fYtPCYghsoo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63FC3741-4F4A-461C-85F5-E644167FD3B1</gtr:id><gtr:title>Analogues of Disulfides from Allium stipitatum Demonstrate Potent Anti-tubercular Activities through Drug Efflux Pump and Biofilm Inhibition.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/139ab9dcd19be3881a221611eb975f4d"><gtr:id>139ab9dcd19be3881a221611eb975f4d</gtr:id><gtr:otherNames>Danquah CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa589c01b9f96.07768818</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>597182A8-FFA0-418B-B13D-696D1F8F943C</gtr:id><gtr:title>Identification of arylamine N-acetyltransferase inhibitors as an approach towards novel anti-tuberculars.</gtr:title><gtr:parentPublicationTitle>Protein &amp; cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a41e02cc55965b9298adffc5897b6e1b"><gtr:id>a41e02cc55965b9298adffc5897b6e1b</gtr:id><gtr:otherNames>Westwood IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1674-800X</gtr:issn><gtr:outcomeId>pm_14203_23_21204000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FB7430A-2779-46EB-B841-352BB7106A9D</gtr:id><gtr:title>Inactivation of Mycobacterium tuberculosis mannosyltransferase pimB reduces the cell wall lipoarabinomannan and lipomannan content and increases the rate of bacterial-induced human macrophage cell death.</gtr:title><gtr:parentPublicationTitle>Glycobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a033ea3739834996f6793c23550b164b"><gtr:id>a033ea3739834996f6793c23550b164b</gtr:id><gtr:otherNames>Torrelles JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-6658</gtr:issn><gtr:outcomeId>FhKSciqKnhQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C3FA61D-061D-41F3-886B-BF6E9BBC146B</gtr:id><gtr:title>Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis.</gtr:title><gtr:parentPublicationTitle>European journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/380577487a346b8bf6a00c43880b67f1"><gtr:id>380577487a346b8bf6a00c43880b67f1</gtr:id><gtr:otherNames>Scalacci N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0223-5234</gtr:issn><gtr:outcomeId>58c60e51422116.42033831</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4992DAAB-E121-4B5C-A34C-17AD83EE3582</gtr:id><gtr:title>Tuberculous meningitis: a uniform case definition for use in clinical research.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26d29de4809bfdda46518e1a7a781512"><gtr:id>26d29de4809bfdda46518e1a7a781512</gtr:id><gtr:otherNames>Marais S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>ia5m1nUpvFM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7FA7C73-414C-48FD-8397-3FA3AFAEB6F9</gtr:id><gtr:title>Anti-tubercular screening of natural products from Colombian plants: 3-methoxynordomesticine, an inhibitor of MurE ligase of Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c255ff65577bfc91cef459008b7f3237"><gtr:id>c255ff65577bfc91cef459008b7f3237</gtr:id><gtr:otherNames>Guzman JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>CFQz6CA4YbK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73E05332-E555-49B5-AEB2-A241D07CA8BC</gtr:id><gtr:title>Characterisation of a putative AraC transcriptional regulator from Mycobacterium smegmatis.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99e1ce46a078a2c54aa3362453f9805c"><gtr:id>99e1ce46a078a2c54aa3362453f9805c</gtr:id><gtr:otherNames>Evangelopoulos D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>5460cb0cd6adc5.78150948</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FD855E1-20CF-4D59-B8D5-BD589E1EC109</gtr:id><gtr:title>Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory and critical care medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bc11b4254344a4dc6f936c04e69c244"><gtr:id>7bc11b4254344a4dc6f936c04e69c244</gtr:id><gtr:otherNames>Sada-Ovalle I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>DuPeL6gQXio</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>628707A0-5BE5-4685-BE4B-7503F7E93B15</gtr:id><gtr:title>Use of DNA arrays to study transcriptional responses to antimycobacterial compounds.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/86a4463ed4e28ac97c0c8cdc53fc2414"><gtr:id>86a4463ed4e28ac97c0c8cdc53fc2414</gtr:id><gtr:otherNames>Waddell SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>KRaodPCeBav</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB69292F-57C4-4FB3-9644-3C61835F94B7</gtr:id><gtr:title>Current status and research strategies in tuberculosis drug development.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00433794477b00a4a58f790cc6072c69"><gtr:id>00433794477b00a4a58f790cc6072c69</gtr:id><gtr:otherNames>Dover LG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>o4M8Fe6XXF4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CFCDB86-B2E6-44A9-BC93-05E8D548ED5A</gtr:id><gtr:title>Characterisation of ATP-dependent Mur ligases involved in the biogenesis of cell wall peptidoglycan in Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e491e1bb172def39d0a494890df580a7"><gtr:id>e491e1bb172def39d0a494890df580a7</gtr:id><gtr:otherNames>Munshi T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14203_23_23555903</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>088C3603-4840-4B42-BC23-4A4CFFAD1C21</gtr:id><gtr:title>Multiple moonlighting functions of mycobacterial molecular chaperones.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f3d4375aa9261cb2162b081848086b2"><gtr:id>2f3d4375aa9261cb2162b081848086b2</gtr:id><gtr:otherNames>Henderson B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>mAwqPTqycYN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77EA96DC-65BB-4656-88C5-82FE2285B3EE</gtr:id><gtr:title>Non-invasive three-dimensional imaging of Escherichia coli K1 infection using diffuse light imaging tomography combined with micro-computed tomography.</gtr:title><gtr:parentPublicationTitle>Methods (San Diego, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8596b0a9f24464759224f2edd2228eee"><gtr:id>8596b0a9f24464759224f2edd2228eee</gtr:id><gtr:otherNames>Witcomb LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1046-2023</gtr:issn><gtr:outcomeId>5a79ac4685c4b0.52818970</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>179B05CC-8C67-48FD-AD65-FDE8BF9574D7</gtr:id><gtr:title>Molecular bacterial load assay, a culture-free biomarker for rapid and accurate quantification of sputum Mycobacterium tuberculosis bacillary load during treatment.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61bd037264be4879efa8c73ec0f96925"><gtr:id>61bd037264be4879efa8c73ec0f96925</gtr:id><gtr:otherNames>Honeyborne I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>VBwrxTbEUxx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>084FD6FF-DB6B-4557-A726-7AE45B9C97DE</gtr:id><gtr:title>DNA sequence-selective C8-linked pyrrolobenzodiazepine-heterocyclic polyamide conjugates show anti-tubercular-specific activities.</gtr:title><gtr:parentPublicationTitle>The Journal of antibiotics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d14bc18f2fcb286516c768464b9626c3"><gtr:id>d14bc18f2fcb286516c768464b9626c3</gtr:id><gtr:otherNames>Brucoli F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-8820</gtr:issn><gtr:outcomeId>58c60e51e1bff9.52272219</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BC79928-9D00-4564-BF1B-3BF5F1B226A6</gtr:id><gtr:title>Comparison of the moonlighting actions of the two highly homologous chaperonin 60 proteins of Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa8fc00a9338caeddb1e4f3406b37eb2"><gtr:id>fa8fc00a9338caeddb1e4f3406b37eb2</gtr:id><gtr:otherNames>Cehovin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>WCZnRaUBRfD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D9C503E-7380-4006-AEBD-5D2001D0C5CA</gtr:id><gtr:title>Comparison of the Arylamine N-acetyltransferase from Mycobacterium marinum and Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>The protein journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e32192f9ea9d583b14eceec2d8e2a8ba"><gtr:id>e32192f9ea9d583b14eceec2d8e2a8ba</gtr:id><gtr:otherNames>Fullam E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1572-3887</gtr:issn><gtr:outcomeId>h2NjNv43uTo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4D4334B-8E83-41AA-B86D-6F6F9BFDF462</gtr:id><gtr:title>Mycobacterium tuberculosis... Can we beat it? Report from a Euroscicon conference 2013.</gtr:title><gtr:parentPublicationTitle>Virulence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ef4886af58d356598faedafe2cb830d"><gtr:id>3ef4886af58d356598faedafe2cb830d</gtr:id><gtr:otherNames>Maitra A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2150-5594</gtr:issn><gtr:outcomeId>pm_14203_23_23863609</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC1DADA6-A10E-4831-939E-FBC4AF3E68B3</gtr:id><gtr:title>Biochemical characterization of the Mycobacterium tuberculosis phosphoribosyl-1-pyrophosphate synthetase.</gtr:title><gtr:parentPublicationTitle>Glycobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/938585ac20ff7a91cc730466157b3634"><gtr:id>938585ac20ff7a91cc730466157b3634</gtr:id><gtr:otherNames>Alderwick LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-6658</gtr:issn><gtr:outcomeId>gX29Wdduqpz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7153A520-74D2-4295-BE4F-514D5DDC4FD0</gtr:id><gtr:title>Multiple routes of complement activation by Mycobacterium bovis BCG.</gtr:title><gtr:parentPublicationTitle>Molecular immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11d7e263d1d9c8d0081b3ca7a823a08e"><gtr:id>11d7e263d1d9c8d0081b3ca7a823a08e</gtr:id><gtr:otherNames>Carroll MV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0161-5890</gtr:issn><gtr:outcomeId>cwcWjhRySeV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A00298C5-6B6C-4E95-A362-4473C21F0B2B</gtr:id><gtr:title>UV-curable gels as topical nail medicines:In vivo residence, anti-fungal efficacy and influence of gel components on their properties.</gtr:title><gtr:parentPublicationTitle>International journal of pharmaceutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c833b716cfa135621972f06966b23eb3"><gtr:id>c833b716cfa135621972f06966b23eb3</gtr:id><gtr:otherNames>Kerai LV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0378-5173</gtr:issn><gtr:outcomeId>58c60e52504be2.15437669</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8DABA77-7CE7-4728-B538-09CFCA88F493</gtr:id><gtr:title>Antitubercular activity of Arctium lappa and Tussilago farfara extracts and constituents.</gtr:title><gtr:parentPublicationTitle>Journal of ethnopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11e74e5a3a7b3794a49aa81194f3c27f"><gtr:id>11e74e5a3a7b3794a49aa81194f3c27f</gtr:id><gtr:otherNames>Zhao J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0378-8741</gtr:issn><gtr:outcomeId>54607901654729.59036679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3015850B-F1E5-4539-86B5-D2C3B2815DD6</gtr:id><gtr:title>Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c255ff65577bfc91cef459008b7f3237"><gtr:id>c255ff65577bfc91cef459008b7f3237</gtr:id><gtr:otherNames>Guzman JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>pm_14203_23_23794563</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41B5F77D-C839-4232-AE66-F3159E3E41AF</gtr:id><gtr:title>An integrated machine learning approach for predicting DosR-regulated genes in Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>BMC systems biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d895db59e431e55ec84105d0da4fab0d"><gtr:id>d895db59e431e55ec84105d0da4fab0d</gtr:id><gtr:otherNames>Zhang Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1752-0509</gtr:issn><gtr:outcomeId>tgd7wZbV6Lt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FC4B87B-F779-42B4-817B-6349D248C46F</gtr:id><gtr:title>The draft genome of Mycobacterium aurum, a potential model organism for investigating drugs against Mycobacterium tuberculosis and Mycobacterium leprae.</gtr:title><gtr:parentPublicationTitle>International journal of mycobacteriology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e125de461f095e9031ebb2c359cafc78"><gtr:id>e125de461f095e9031ebb2c359cafc78</gtr:id><gtr:otherNames>Phelan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2212-5531</gtr:issn><gtr:outcomeId>58c60e51b275d5.10351488</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>431D5548-C967-4D34-80F4-E0C8819A1EC7</gtr:id><gtr:title>Mapping the fitness of Mycobacterium tuberculosis strains: a complex picture.</gtr:title><gtr:parentPublicationTitle>Journal of medical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea054cdcc4a6358feae93e08898253e2"><gtr:id>ea054cdcc4a6358feae93e08898253e2</gtr:id><gtr:otherNames>O'Sullivan DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-2615</gtr:issn><gtr:outcomeId>Buwo9Z98q4E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D67926A2-8DA3-43F6-B2D6-786BE4D3B1EF</gtr:id><gtr:title>Identification of 2-aminothiazole-4-carboxylate derivatives active against Mycobacterium tuberculosis H37Rv and the beta-ketoacyl-ACP synthase mtFabH.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3125c235119e244a21e2a4774907109e"><gtr:id>3125c235119e244a21e2a4774907109e</gtr:id><gtr:otherNames>Al-Balas Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>JZ4cJNMC47n</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F25F5D3-F4C5-4E98-AD88-C77F086FA4C0</gtr:id><gtr:title>ATP-dependent MurE ligase in Mycobacterium tuberculosis: biochemical and structural characterisation.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c230ed5b13e3811e414934bcc85bd152"><gtr:id>c230ed5b13e3811e414934bcc85bd152</gtr:id><gtr:otherNames>Basavannacharya C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>ZnsipiyZrWw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1388860-FBAE-40AF-AA56-B8AE76BD6C4F</gtr:id><gtr:title>Modular approach to triazole-linked 1,6-a-D-oligomannosides to the discovery of inhibitors of Mycobacterium tuberculosis cell wall synthetase.</gtr:title><gtr:parentPublicationTitle>The Journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b7ca0b14131710bba6bac64491cfc31"><gtr:id>2b7ca0b14131710bba6bac64491cfc31</gtr:id><gtr:otherNames>Lo Conte M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3263</gtr:issn><gtr:outcomeId>eKvsNfTeJdA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72B06A89-E625-4755-A3D0-6865AF8A99E5</gtr:id><gtr:title>An integrated surrogate model for screening of drugs against Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2647108e79ca174352f02bf675cba5e9"><gtr:id>2647108e79ca174352f02bf675cba5e9</gtr:id><gtr:otherNames>Gupta A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_14203_23_22398649</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E06C2C9-3F54-4202-AC8F-654F3B671BD3</gtr:id><gtr:title>Exploration of piperidinols as potential antitubercular agents.</gtr:title><gtr:parentPublicationTitle>Molecules (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8147bbcf9fb9ace998a288e104ccd5a5"><gtr:id>8147bbcf9fb9ace998a288e104ccd5a5</gtr:id><gtr:otherNames>Abuhammad A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1420-3049</gtr:issn><gtr:outcomeId>5460790111aa56.34683017</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF657FFF-BAAC-440C-AA61-B22AAA356EFC</gtr:id><gtr:title>Antimycobacterials from natural sources: ancient times, antibiotic era and novel scaffolds.</gtr:title><gtr:parentPublicationTitle>Frontiers in bioscience (Landmark edition)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c255ff65577bfc91cef459008b7f3237"><gtr:id>c255ff65577bfc91cef459008b7f3237</gtr:id><gtr:otherNames>Guzman JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1093-4715</gtr:issn><gtr:outcomeId>pm_14203_23_22201841</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A57B041B-4E53-456B-9D51-978C945D7DB8</gtr:id><gtr:title>Fast-growing, non-infectious and intracellularly surviving drug-resistant Mycobacterium aurum: a model for high-throughput antituberculosis drug screening.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2647108e79ca174352f02bf675cba5e9"><gtr:id>2647108e79ca174352f02bf675cba5e9</gtr:id><gtr:otherNames>Gupta A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>Sr4TuuMQ1Y5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97E717B4-392B-4D95-9DCF-5EA93A3D31F1</gtr:id><gtr:title>Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs.</gtr:title><gtr:parentPublicationTitle>British medical bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ef4886af58d356598faedafe2cb830d"><gtr:id>3ef4886af58d356598faedafe2cb830d</gtr:id><gtr:otherNames>Maitra A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-1420</gtr:issn><gtr:outcomeId>58c60e5219d961.93210041</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D9C58DF-4FAD-4865-AA76-95323C365796</gtr:id><gtr:title>Mycobacterium tuberculosis: immune evasion, latency and reactivation.</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2647108e79ca174352f02bf675cba5e9"><gtr:id>2647108e79ca174352f02bf675cba5e9</gtr:id><gtr:otherNames>Gupta A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn><gtr:outcomeId>pm_14203_23_21813205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BF922AA-8663-4A62-86DF-6675A20426E1</gtr:id><gtr:title>3-Ketosteroid 9alpha-hydroxylase is an essential factor in the pathogenesis of Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Molecular microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/138f33a3f01c841c7c7260f7700fecd5"><gtr:id>138f33a3f01c841c7c7260f7700fecd5</gtr:id><gtr:otherNames>Hu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0950-382X</gtr:issn><gtr:outcomeId>rRKpjJAqrHu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7591E3EA-275D-4DAA-AFB2-488E18ABEE36</gtr:id><gtr:title>Rapid methods for testing inhibitors of mycobacterial growth.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99e1ce46a078a2c54aa3362453f9805c"><gtr:id>99e1ce46a078a2c54aa3362453f9805c</gtr:id><gtr:otherNames>Evangelopoulos D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>pm_14203_23_20401596</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1835C94-93B8-476B-9167-09196FDFA3F4</gtr:id><gtr:title>Early diagnosis and effective treatment regimens are the keys to tackle antimicrobial resistance in tuberculosis (TB): A report from Euroscicon's international TB Summit 2016.</gtr:title><gtr:parentPublicationTitle>Virulence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ef4886af58d356598faedafe2cb830d"><gtr:id>3ef4886af58d356598faedafe2cb830d</gtr:id><gtr:otherNames>Maitra A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2150-5594</gtr:issn><gtr:outcomeId>58c60e51840ff0.74760464</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F719848-205D-45D1-A05A-6A7F89DD9A24</gtr:id><gtr:title>Characterization of a beta-hydroxybutyryl-CoA dehydrogenase from Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Microbiology (Reading, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bca96292966fdd05e191aaac826d4e92"><gtr:id>bca96292966fdd05e191aaac826d4e92</gtr:id><gtr:otherNames>Taylor RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1350-0872</gtr:issn><gtr:outcomeId>VfdmxtjcALg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>392E7F53-867B-4208-819B-83155644CE46</gtr:id><gtr:title>Characterization of the Corynebacterium glutamicum deltapimB' deltamgtA double deletion mutant and the role of Mycobacterium tuberculosis orthologues Rv2188c and Rv0557 in glycolipid biosynthesis.</gtr:title><gtr:parentPublicationTitle>Journal of bacteriology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1764466a9db2af8c2be90c94ee57fb4e"><gtr:id>1764466a9db2af8c2be90c94ee57fb4e</gtr:id><gtr:otherNames>Mishra AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9193</gtr:issn><gtr:outcomeId>UdBE5kS19FL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>316F324E-5F1B-42EA-9AD4-B38F6120825F</gtr:id><gtr:title>An antibacterial from Hypericum acmosepalum inhibits ATP-dependent MurE ligase from Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>International journal of antimicrobial agents</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/715aed8d675bff959a034a40272a64c8"><gtr:id>715aed8d675bff959a034a40272a64c8</gtr:id><gtr:otherNames>Osman K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0924-8579</gtr:issn><gtr:outcomeId>pm_14203_23_22079533</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F344BAB0-E1CA-4C27-93A0-D2985BD6E0FD</gtr:id><gtr:title>Antimycobacterials from lovage root (Ligusticum officinale Koch).</gtr:title><gtr:parentPublicationTitle>Phytotherapy research : PTR</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c255ff65577bfc91cef459008b7f3237"><gtr:id>c255ff65577bfc91cef459008b7f3237</gtr:id><gtr:otherNames>Guzman JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0951-418X</gtr:issn><gtr:outcomeId>pm_14203_23_22899555</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51083468-613D-430E-9E1D-E36FEDCB07DE</gtr:id><gtr:title>Characterization of a carbon-carbon hydrolase from Mycobacterium tuberculosis involved in cholesterol metabolism.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3494741d7722dcb25e589a2f1f720d99"><gtr:id>3494741d7722dcb25e589a2f1f720d99</gtr:id><gtr:otherNames>Lack NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>MfzYpDYiHPk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51B7ECF8-1B34-41CD-AECF-2E1D5221AE03</gtr:id><gtr:title>Nano-Formulation of Ethambutol with Multifunctional Graphene Oxide and Magnetic Nanoparticles Retains Its Anti-Tubercular Activity with Prospects of Improving Chemotherapeutic Efficacy.</gtr:title><gtr:parentPublicationTitle>Molecules (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e280aeb25723ca3e299a4ce7d6024ac"><gtr:id>2e280aeb25723ca3e299a4ce7d6024ac</gtr:id><gtr:otherNames>Saifullah B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1420-3049</gtr:issn><gtr:outcomeId>5aa589c0ccd528.31586402</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D472F791-6AD3-4A5A-B2F3-1F587862FABB</gtr:id><gtr:title>Methods to determine fitness in bacteria.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e277211422fa1def3c492f72d0b6ff56"><gtr:id>e277211422fa1def3c492f72d0b6ff56</gtr:id><gtr:otherNames>Pope CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>SKrBvSrezoM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EFE200B-3625-4AF0-9FB2-E5CC3BB22A0C</gtr:id><gtr:title>Versatile routes to marine sponge metabolites through benzylidene rhodanines.</gtr:title><gtr:parentPublicationTitle>Organic letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77dfe3df46d3fe140733e15f40cc675f"><gtr:id>77dfe3df46d3fe140733e15f40cc675f</gtr:id><gtr:otherNames>Kottakota SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1523-7052</gtr:issn><gtr:outcomeId>pm_14203_23_23234337</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58637B22-57DA-443F-816F-56D5D1DE7C5C</gtr:id><gtr:title>New approaches to the total synthesis of the bryostatin antitumor macrolides.</gtr:title><gtr:parentPublicationTitle>Chemistry, an Asian journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a413e438aa59c92c7521a2f8ba3a93d6"><gtr:id>a413e438aa59c92c7521a2f8ba3a93d6</gtr:id><gtr:otherNames>Hale KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1861-471X</gtr:issn><gtr:outcomeId>Lh8ZQXkSNDw</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802079</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>